Please login to the form below

Not currently logged in
Email:
Password:

Evotec enters new alliance with Genentech

Evotec and Genentech have formed a new integrated drug discovery alliance to support research into novel small molecule therapeutics

Evotec has announced today that it has formed a new alliance with Genentech (owned by Roche) to support Genentech's research to discover novel small molecule therapeutics.

Said Dr Werner Lanthaler, Evotec's CEO: "We are proud that Genentech, one of the premier biopharmaceutical companies worldwide, has selected Evotec's scientists and innovative drug discovery platform to support its research efforts. We look forward to working closely with Genentech's scientists and achieving success together."

The collaboration includes assay development and high throughput screening, medicinal chemistry and structural biology. Terms for the collaboration have not been disclosed.

Roche (one of several pharma companies working jointly with Evotec to develop its pipeline of products) already has several collaborative research areas in place, including one for product development in treatment-resistant depression and another to jointly discover and develop compounds against a target for CNS diseases and other indications.

Evotec is due to report its financial/performance results for the first quarter of 2010 on Wednesday May 12.

10th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics